EMERYVILLE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Ethan Weiss, M.D., to the company's Scientific Advisory Board. Dr. Weiss is a cardiologist with expertise in clotting and coagulation diseases, and is a leading researcher at the Cardiovascular Research Institute and the Division of Cardiology at the University of California, San Francisco (UCSF).
"We are very excited to have Ethan on the scientific advisory board as we are advancing our drugs," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "Dr. Weiss's research focuses on the mechanism of clotting activation by estrogens. His work is critical to the clotting safety elucidation of Bionovo's estrogen receptor beta selective drugs."
Dr. Weiss added, "Our results, so far, are very comforting. In early experiments we can see that in contrast to estrogen, MF101 has no effect on clotting. Therefore, MF101 will most likely be a safer alternative for the treatment of menopausal symptoms."
Dr. Ethan Weiss joined the faculty at UCSF in 2003 as Assistant
Professor of Medicine. Dr. Weiss earned his medical degree from the Johns
Hopkins University School of Medicine, and he completed his internship and
residency at the John Hopkins Hospital. Dr. Weiss came to the University of
California, San Francisco in 1998 as a cardiology fellow where he spent
three years under the scientific mentorship of Dr. Shaun Coughlin in the
Cardiovascular Research Institute studying the effects of thrombin
signaling in platelets. He then completed his clinical fellowship and
served as Chief Cardiology Fellow in 2002. Dr Weiss' clinical focus
includes acute care cardiology, coronary artery disease and general
|SOURCE Bionovo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved